KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Cash & Equivalents (2017 - 2025)

Bionano Genomics' Cash & Equivalents history spans 7 years, with the latest figure at $3.1 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 65.15% year-over-year to $3.1 million; the TTM value through Sep 2025 reached $3.1 million, down 65.15%, while the annual FY2024 figure was $9.2 million, 48.89% down from the prior year.
  • Cash & Equivalents for Q3 2025 was $3.1 million at Bionano Genomics, down from $3.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $362.1 million in Q1 2021 and bottomed at $3.1 million in Q3 2025.
  • The 5-year median for Cash & Equivalents is $15.8 million (2024), against an average of $56.3 million.
  • The largest annual shift saw Cash & Equivalents soared 4345.69% in 2021 before it plummeted 93.36% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $24.6 million in 2021, then crashed by 79.28% to $5.1 million in 2022, then surged by 252.54% to $17.9 million in 2023, then plummeted by 48.89% to $9.2 million in 2024, then crashed by 66.59% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Cash & Equivalents are $3.1 million (Q3 2025), $3.6 million (Q2 2025), and $3.6 million (Q1 2025).